News

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.

AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.

What AbbVie’s Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi’s role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The filing, backed by Phase 3 AFFIRM data, comes as AbbVie stock reflects a mixed recent pattern, with the share price down over the past week but higher over the past month, past 3 months and past year. At a...

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

The signs were not in the headline growth rate but in which two products were trading places.

Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.

ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.

The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.

Three blue-chip dividend stocks, each on a different quarterly payment schedule, can fill every month of the year with income, but each one carries a distinct risk that could derail the whole ladder.

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

The company now leads with a cost-savings total and a growth rate that does not begin until the end of the decade, which tells a holder far less about whether its medicines are winning.

Sticky inflation is quietly rewarding a specific group of stocks with decades of uninterrupted dividend growth, and Wall Street's top analysts say five of them are built to profit no matter how long rising prices persist.

AbbVie (NYSE: ABBV) has submitted a regulatory application to the European Medicines Agency for SKYRIZI (risankizumab) subcutaneous induction in adults with moderately to severely active Crohn's disease. The filing seeks to add a less invasive induction treatment option to AbbVie's Crohn's disease portfolio in Europe. The submission is supported by positive Phase 3 data for SKYRIZI in this patient group. This step may influence AbbVie's position in the European immunology market as the...

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That drug now represents a small fraction of the Innovative Medicine portfolio. The remaining 96% of that business is posting remarkable growth, expanding at over 14.

The past year's gain was bought with volume and access, and management has already said net price goes lower from here.

His AbbVie purchase was a big move into a high-yielding dividend stock.

Its growth profile stands well above major sector peers.

Beyond strong drugs, the stock’s ascent was powered by its notable profitability.

AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.

Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Earlier in August 2026, AbbVie reported new clinical, translational and real-world data from its lung cancer portfolio at the World Conference on Lung Cancer, including high objective response rates and generally manageable safety profiles for investigational therapies ABBV-1480 and ABBV-706, plus progress on Temab-A trials in non-small cell lung cancer. The breadth of these lung cancer programs, spanning bispecific antibodies and antibody-drug conjugates across first-line and relapsed...

Management is betting on a bigger year than ever, but investors seem to be waiting for a catch.

Chasing a fatter dividend yield can quietly destroy the very income stream you built it to replace. Before you commit a dollar, understand why the yield number that looks most attractive often signals the greatest danger to your principal.